CXCR3 and atherosclerosis: Although several studies of CXCR3 antagonists have shown their efficacy in in vivo models of disease, notably atherosclerosis (van Wanrooij et al., 2008) and transplant rejection (Jenh et al., 2012), only one such antagonist has entered clinical trials in man, the compound AMG-487, originally identified by scientists at Chemocentryx and subsequently licensed to Amgen.